This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gerard E. Hogarty, MSW; Richard F. Ulrich

Arch Gen Psychiatry. 1977;34(3):297-301.

Abstract
• The potential for unwanted side effects, particularly tardive dyskinesia, following long-term aftercare maintenance with antipsychotic medication has led to serious questioning of its continued use for schizophrenic patients. Does the risk of relapse decline with the passage of time? If so, is the advantage of drug therapy sustained and large enough to justify continued treatment beyond one or two years? More appropriate methods for analyzing the aftercare experience of 374 schizophrenic patients treated with drug or placebo reveals that while the risk of relapse does decline substantially, it remains twice as high for placebo-treated patients than drug-treated patients even after two years of treatment. The prophylactic effect of maintenance chemotherapy appears to be one to two times larger than generally estimated by the less precise "cumulative percentage" method.

Author Affiliations
From the Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine.

Footnotes
Accepted for publication Nov 15, 1976.

Reprint requests to 3811 O'Hara St, Pittsburgh, PA 15261 (Mr Hogarty).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Durability and Mechanism of Effects of Cognitive Enhancement Therapy
Hogarty et al.
Psychiatr. Serv. 2006;57:1751-1757.
ABSTRACT | FULL TEXT  

Cognitive Enhancement Therapy for Schizophrenia: Effects of a 2-Year Randomized Trial on Cognition and Behavior
Hogarty et al.
Arch Gen Psychiatry 2004;61:866-876.
ABSTRACT | FULL TEXT  

Agreement Between Seriously Mentally Ill Veterans and Their Clinicians About Medication Compliance
Valenstein et al.
Psychiatr. Serv. 1998;49:1043-1048.
ABSTRACT | FULL TEXT  

Family Psychoeducation, Social Skills Training, and Maintenance Chemotherapy in the Aftercare Treatment of Schizophrenia: II. Two-Year Effects of a Controlled Study on Relapse and Adjustment
Hogarty et al.
Arch Gen Psychiatry 1991;48:340-347.
ABSTRACT  

Is Clozapine Response Different in Neuroleptic Nonresponders vs Partial Responders?
Osser and Albert
Arch Gen Psychiatry 1990;47:189-189.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT  

Family Psychoeducation, Social Skills Training, and Maintenance Chemotherapy in the Aftercare Treatment of Schizophrenia: I. One-Year Effects of a Controlled Study on Relapse and Expressed Emotion
Hogarty et al.
Arch Gen Psychiatry 1986;43:633-642.
ABSTRACT  

Motility, Parkinsonism, and Prolactin With Thiothixene and Thioridazine
Crowley and Hydinger-Macdonald
Arch Gen Psychiatry 1981;38:668-675.
ABSTRACT  

Fluphenazine and Social Therapy in the Aftercare of Schizophrenic Patients: Relapse Analyses of a Two-Year Controlled Study of Fluphenazine Decanoate and Fluphenazine Hydrochloride
Hogarty et al.
Arch Gen Psychiatry 1979;36:1283-1294.
ABSTRACT  

Day Treatment and Psychotropic Drugs in the Aftercare of Schizophrenic Patients: A Veterans Administration Cooperative Study
Linn et al.
Arch Gen Psychiatry 1979;36:1055-1066.
ABSTRACT